A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent<i>Clostridium difficile</i>Infection

Khanna, Sahil; Pardi, Darrell S.; Kelly, Colleen R.; Kraft, Colleen S.; Dhere, Tanvi; Henn, Matthew R.; Lombardo, Mary Jane; Vulić, Marin; Ohsumi, Toshiro K.; Winkler, Julian; Pindar, Christina; McGovern, Barbara; Pomerantz, Roger J.; Auniņš, John G.; Cook, David N.; Hohmann, Elizabeth L.

doi:10.1093/infdis/jiv766

Cited by 282 publications

(187 citation statements)

References 47 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…The first of these was a non-comparative study in patients with >3 CDI episodes in the previous 12 months. 62 will be important to understand these results.…”

Section: Ser-109 (Seres) Is Also a Live Biotheraputic That Comprises mentioning

confidence: 99%

New and emerging therapies for Clostridium difficile infection

Martin

Wilcox²

2016

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

(max 200 words)Purpose of review: Clostridium difficile infection has attained high prominence given its prevalence and impacts on patients and healthcare institutions. Multiple new approaches to the prevention and treatment of CDI are undergoing clinical trials. Recent findings:Bezlotoxumab is a monoclonal antibody against toxin B that has successfully completed phase three studies, demonstrating a significant reduction in recurrent CDI when given with standard of care antibiotics. Antibiotics under development include cadazolid and ridinilazole, while surotomycin has had disappointing phase 3 results. Multiple live biotherapeutics are being developed, including freeze thawed and encapsulated versions of faecal microbiota transplantation to improve the practicality of treating patients with recurrent CDI. Alternatives to faecal microbiota transplantation, that aim to improve safety, including a microbial suspension, RBX2660, and a complex spore formulation, SER-109, have progressed to phase 2 studies. A non-toxigenic C. difficile strain has also shown promise to prevent recurrent CDI. In addition, three C. difficile vaccines have progressed to phase 2/3 clinical trials. Summary:The diverse approaches to treating and preventing CDI offer substantial promise that new treatment options will soon emerge, particular ones that reduce the risk of recurrences.3

show abstract

“…The first of these was a non-comparative study in patients with >3 CDI episodes in the previous 12 months. 62 will be important to understand these results.…”

Section: Ser-109 (Seres) Is Also a Live Biotheraputic That Comprises mentioning

confidence: 99%

New and emerging therapies for Clostridium difficile infection

Martin

Wilcox²

2016

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…After some success in preclinical studies, the mixture, known as ser-109, was formulated for oral administration to patients between 18 and 90 years with recurrent CDI. The researchers observed a reduction at recurrence of the CDI of 87.7% over 8 weeks of treatment [40]. Gerding et al recently began a phase 2 trial of administration of spores from a single non-toxigenic C. difficile, in patients who had responded to antibiotics in the first episode or the first recurrence [41].…”

Section: Spore Formulationmentioning

confidence: 99%

Clostridium difficile Infection: Pathogenesis, Diagnosis and Treatment

Fernández-García¹,

Blasco²,

López³

et al. 2017

Clostridium Difficile - A Comprehensive Overview

View full text Add to dashboard Cite

Clostridium difficile is a Gram-positive bacterium with the capacity of spore generation.The C. difficile infections, related to antibiotic treatment, have increased in number and severity during the last few years; increasing the health problems caused by this bacterium. One of the most important problems of the C. difficile infection is the recurrence. Due to all of these facts, researchers have been searching for new treatments such as faecal microbiota transplantation or bacteriocins development.

show abstract

“…d'efficacité de 81 à 90 % chez les patients atteints de CDI [38][39][40]. Devant le geste invasif que représente la FMT et face au risque de transmission de pathogènes, des méthodes alternatives ont été évaluées comme par exemple l'administration orale d'un composé de spores issus d'une cinquantaine d'espèces de Firmicutes isolés à partir de donneurs sains [41]. À côté des pré-et probiotiques, les antibiotiques repré-sentent une alternative thérapeutique envisageable.…”

Section: Microbiote Intestinal Immunothérapies Et Toxicitésunclassified